<article xmlns="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://dtd.nlm.nih.gov/2.0/xsd/archivearticle http://dtd.nlm.nih.gov/2.0/xsd/archivearticle.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Biochim Biophys Acta</journal-id>
      <journal-title-group>
        <journal-title>Biochimica et Biophysica Acta</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0006-3002</issn>
      <publisher>
        <publisher-name>Elsevier Pub. Co</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmc">3265671</article-id>
      <article-id pub-id-type="pmid">22086148</article-id>
      <article-id pub-id-type="publisher-id">BBABIO46797</article-id>
      <article-id pub-id-type="doi">10.1016/j.bbabio.2011.10.012</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The effects of idebenone on mitochondrial bioenergetics</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Giorgio</surname>
            <given-names>Valentina</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Petronilli</surname>
            <given-names>Valeria</given-names>
          </name>
          <xref rid="af0005" ref-type="aff">a</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ghelli</surname>
            <given-names>Anna</given-names>
          </name>
          <xref rid="af0010" ref-type="aff">b</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Carelli</surname>
            <given-names>Valerio</given-names>
          </name>
          <xref rid="af0015" ref-type="aff">c</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rugolo</surname>
            <given-names>Michela</given-names>
          </name>
          <email>michela.rugolo@unibo.it</email>
          <xref rid="af0010" ref-type="aff">b</xref>
          <xref rid="cr0005" ref-type="corresp">⁎</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lenaz</surname>
            <given-names>Giorgio</given-names>
          </name>
          <xref rid="af0020" ref-type="aff">d</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernardi</surname>
            <given-names>Paolo</given-names>
          </name>
          <email>bernardi@bio.unipd.it</email>
          <xref rid="af0005" ref-type="aff">a</xref>
          <xref rid="cr0010" ref-type="corresp">⁎⁎</xref>
        </contrib>
      </contrib-group>
      <aff id="af0005"><label>a</label>Consiglio Nazionale delle Ricerche Institute of Neurosciences and Department of Biomedical Sciences, University of Padova, Padova, Italy</aff>
      <aff id="af0010"><label>b</label>Department of Evolutionary and Experimental Biology, University of Bologna, Bologna, Italy</aff>
      <aff id="af0015"><label>c</label>Department of Neurological Sciences, University of Bologna, Bologna, Italy</aff>
      <aff id="af0020"><label>d</label>Department of Biochemistry “G. Moruzzi”, University of Bologna, Bologna, Italy</aff>
      <author-notes>
        <corresp id="cr0005"><label>⁎</label>Correspondence to: M. Rugolo, Department of Evolutionary and Experimental Biology, University of Bologna, Via Irnerio 42, I-40126 Bologna, Italy.Bologna, Italy. Fax: + 39 051242576. <email>michela.rugolo@unibo.it</email></corresp>
        <corresp id="cr0010"><label>⁎⁎</label>Correspondence to: P. Bernardi, Department of Biomedical Sciences, University of Padova, Viale Giuseppe Colombo 3, I-35121 Padova, Italy. Fax: + 39 0498276361. <email>bernardi@bio.unipd.it</email></corresp>
      </author-notes>
      <pub-date pub-type="pmc-release">
        <month>2</month>
        <year>2012</year>
      </pub-date>
      <!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. -->
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2012</year>
      </pub-date>
      <volume>1817</volume>
      <issue>2</issue>
      <fpage>363</fpage>
      <lpage>369</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>8</month>
          <year>2011</year>
        </date>
        <date date-type="rev-recd">
          <day>27</day>
          <month>10</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>28</day>
          <month>10</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2012 Elsevier B.V.</copyright-statement>
        <copyright-year>2011</copyright-year>
        <copyright-holder>Elsevier B.V.</copyright-holder>
        <license>
          <license-p>This document may be redistributed and reused, subject to <ext-link ext-link-type="uri" xlink:href="http://www.elsevier.com/wps/find/authorsview.authors/supplementalterms1.0">certain conditions</ext-link>.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We have studied the effects of idebenone on mitochondrial function in cybrids derived from one normal donor (HQB17) and one patient harboring the G3460A/MT-ND1 mutation of Leber's Hereditary Optic Neuropathy (RJ206); and in XTC.UC1 cells bearing a premature stop codon at aminoacid 101 of MT-ND1 that hampers complex I assembly. Addition of idebenone to HQB17 cells caused mitochondrial depolarization and NADH depletion, which were inhibited by cyclosporin (Cs) A and decylubiquinone, suggesting an involvement of the permeability transition pore (PTP). On the other hand, addition of dithiothreitol together with idebenone did not cause PTP opening and allowed maintenance of the mitochondrial membrane potential even in the presence of rotenone. Addition of dithiothreitol plus idebenone, or of idebenol, to HQB17, RJ206 and XTC.UC1 cells sustained membrane potential in intact cells and ATP synthesis in permeabilized cells even in the presence of rotenone and malonate, and restored a good level of coupled respiration in complex I-deficient XTC.UC1 cells. These findings demonstrate that idebenol can feed electrons at complex III. If the quinone is maintained in the reduced state, a task that in some cell types appears to be performed by dicoumarol-sensitive NAD(P)H:quinone oxidoreductase 1 [Haefeli et al. (2011) PLoS One 6, e17963], electron transfer to complex III may allow reoxidation of NADH in complex I deficiencies.</p>
      </abstract>
      <abstract abstract-type="graphical">
        <title>Highlights</title>
        <p>► The mitochondrial effects of idebenone in living cells are poorly characterized. ► Idebenone can be toxic or beneficial depending on its oxidation-reduction state. ► Idebenone is toxic through opening of the permeability transition pore. ► Idebenol stimulates respiration and ATP synthesis in cells lacking complex I. ► Short-chain quinones can be developed for the treatment of complex I defects.</p>
      </abstract>
      <kwd-group>
        <title>Abbreviations</title>
        <kwd>CRC, calcium retention capacity</kwd>
        <kwd>Cs, cyclosporin</kwd>
        <kwd>DMEM, Dulbecco's modified Eagle's medium</kwd>
        <kwd>Δψ<sub>m</sub>, mitochondrial membrane potential difference</kwd>
        <kwd>DTT, dithiothreitol</kwd>
        <kwd>FCCP, carbonylcyanide-<italic>p</italic>-trifluoromethoxyphenyl hydrazone</kwd>
        <kwd>LHON, Leber's hereditary optic neuropathy</kwd>
        <kwd>MELAS, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes</kwd>
        <kwd>MOPS, 4-morpholinepropanesulfonic acid</kwd>
        <kwd>NQO1, NAD(P)H:quinone oxidoreductase 1</kwd>
        <kwd>OCR, oxygen consumption rate</kwd>
        <kwd>PTP, permeability transition pore</kwd>
        <kwd>ROS, reactive oxygen species</kwd>
        <kwd>TMRM, tetramethylrhodamine methyl ester</kwd>
      </kwd-group>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Mitochondria</kwd>
        <kwd>Idebenone</kwd>
        <kwd>Permeability transition</kwd>
        <kwd>Electron transfer</kwd>
        <kwd>ATP synthesis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="s0005">
      <label>1</label>
      <title>Introduction</title>
      <p>Coenzyme Q is a lipophilic molecule mostly, but not exclusively localized in the inner mitochondrial membrane <xref rid="bb0005 bb0010" ref-type="bibr">[1,2]</xref>. It is composed of a redox active benzoquinone ring conjugated to an isoprenoid side chain whose length may differ among species. In man ubiquinone contains predominantly 10 isoprenyl units and is designated CoQ10. CoQ10 shuttles electrons from complex I and II and other flavoprotein dehydrogenases to complex III of the mitochondrial respiratory chain; it also functions as a lipid-soluble antioxidant, scavenges reactive oxygen species (ROS), and is involved in multiple aspects of cellular metabolism <xref rid="bb0005 bb0010" ref-type="bibr">[1,2]</xref>.</p>
      <p>Primary CoQ10 deficiencies are associated with pathogenic mutations affecting genes involved in the biosynthesis of CoQ10, and cause clinically heterogeneous diseases <xref rid="bb0010" ref-type="bibr">[2]</xref>. Respiratory chain and ATP synthesis defects, ROS production, and apoptosis contribute to disease pathogenesis, and most patients affected by primary CoQ10 deficiencies respond to CoQ10 supplementation <xref rid="bb0005 bb0015 bb0020" ref-type="bibr">[1,3,4]</xref>. Because of the prominent role attributed to ROS in the pathogenesis of mitochondrial diseases, including Friedreich's ataxia; and because of the antioxidant effect of CoQ10 <xref rid="bb0025" ref-type="bibr">[5]</xref>, its possible use in these diseases has been considered <xref rid="bb0005 bb0030 bb0035" ref-type="bibr">[1,6,7]</xref>. Given the fact that CoQ10 is very insoluble, several short-chain hydrosoluble quinones have been tested, in particular 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone). Idebenone did not prove useful in CoQ10 deficiencies <xref rid="bb0020" ref-type="bibr">[4]</xref>; yet, due to its redox properties and the evidence that it can mediate electron transfer to respiratory chain complex III in isolated mitochondria [<xref rid="bb0005 bb0040 bb0045 bb0050 bb0055 bb0060" ref-type="bibr">1,8–12</xref>], idebenone has been used in several diseases associated to respiratory chain dysfunction like Leber's hereditary optic neuropathy (LHON) <xref rid="bb0065 bb0070 bb0075 bb0080 bb0085" ref-type="bibr">[13–17]</xref>, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) <xref rid="bb0090 bb0095 bb0100" ref-type="bibr">[18–20]</xref>, Leigh syndrome <xref rid="bb0105" ref-type="bibr">[21]</xref>, Friedreich's ataxia <xref rid="bb0030 bb0035 bb0110 bb0115" ref-type="bibr">[6,7,22,23]</xref>, as well as Huntington's <xref rid="bb0315" ref-type="bibr">[24]</xref> and Alzheimer disease <xref rid="bb0125 bb0130 bb0135 bb0140" ref-type="bibr">[25–28]</xref>. More recently, a double blind, placebo-controlled, randomized trial with idebenone in LHON patients (RODHOS study) has shown some efficacy <xref rid="bb0145" ref-type="bibr">[29]</xref>, as also reported in the retrospective analysis of a large case series of LHON patients treated with idebenone during the acute phase of the disease <xref rid="bb0150" ref-type="bibr">[30]</xref>.</p>
      <p>Protective effects of idebenone against cell death induced by glutathione depletion have been reported in CEM leukemia cells <xref rid="bb0155" ref-type="bibr">[31]</xref> and skin fibroblasts from Friedreich's ataxia patients <xref rid="bb0160" ref-type="bibr">[32]</xref>, as well as in staurosporine-induced apoptosis of cultural retinal neurons <xref rid="bb0165" ref-type="bibr">[33]</xref>; yet higher doses of idebenone were cytotoxic to skin fibroblasts derived from both Friedreich's ataxia patients and healthy donors <xref rid="bb0170" ref-type="bibr">[34]</xref>. The recent demonstration that idebenone undergoes reduction by cytosolic dicoumarol-sensitive NAD(P)H:quinone oxidoreductase 1 (NQO1) <xref rid="bb0175" ref-type="bibr">[35]</xref> provides a rationale for its use in complex I-deficient cells, yet potentially toxic effects of idebenone may depend on inhibition of complex I itself <xref rid="bb0040 bb0045 bb0050 bb0055 bb0060" ref-type="bibr">[8–12]</xref> and on opening of the mitochondrial permeability transition pore (PTP) <xref rid="bb0180" ref-type="bibr">[36]</xref>, an inner membrane high-conductance channel involved in cell death <xref rid="bb0185" ref-type="bibr">[37]</xref>.</p>
      <p>The effects of idebenone have been studied surprisingly little in cells, in spite of their obvious importance for the potential therapeutic use of this drug. Here, we present a characterization of the mitochondrial effects of idebenone in human osteosarcoma-derived cybrids bearing wild-type mtDNA (HQB17) or the missense G3460A/MT-ND1 mutation of LHON (RJ206) <xref rid="bb0190 bb0195" ref-type="bibr">[38,39]</xref>; and in XTC.UC1 cells bearing a truncating mutation in the same gene that hampers complex I assembly <xref rid="bb0200 bb0205" ref-type="bibr">[40,41]</xref>.</p>
    </sec>
    <sec sec-type="materials|methods" id="s0010">
      <label>2</label>
      <title>Materials and methods</title>
      <sec sec-type="materials" id="s0015">
        <label>2.1</label>
        <title>Materials</title>
        <p>Oligomycin, rotenone, antimycin A, malonate, malate, pyruvate, carbonylcyanide-<italic>p</italic>-trifluoromethoxyphenyl hydrazone (FCCP), decylubiquinone, dithiothreitol (DTT), ATP monitoring kit, P<sup>1</sup>,P<sup>5</sup> - di(adenosine-5′) pentaphosphate pentasodium and protease inhibitors were from Sigma (Milan, Italy). Idebenone was from Apin Chemicals LTD (Oxon, UK). CsA was purchased from Calbiochem, whereas CsH was a generous gift of Dr. Urs Ruegg, Geneva. Calcium Green 5N was from Invitrogen (Milan, Italy). Tetramethylrhodamine methyl ester (TMRM) was purchased from Molecular Probes (Eugene, OR).</p>
      </sec>
      <sec id="s0020">
        <label>2.2</label>
        <title>Isolation of mitochondria and swelling measurements</title>
        <p>Mouse liver mitochondria were isolated in a buffer containing 250 mM sucrose, 10 mM Tris, 0.1 mM EGTA, pH 7.4, as described previously <xref rid="bb0210" ref-type="bibr">[42]</xref>. Swelling was monitored as the decrease of 90° light scattering of the mitochondrial suspension at 545 nm with a Perkin-Elmer 650–40 fluorescence spectrofluorimeter equipped with magnetic stirring and thermostatic control.</p>
      </sec>
      <sec id="s0025">
        <label>2.3</label>
        <title>Measurements of calcium retention capacity</title>
        <p>The mitochondrial Ca<sup>2 +</sup> retention capacity (CRC) was determined by measuring external Ca<sup>2 +</sup> following addition of 10 μM Ca<sup>2 +</sup> pulses each minute to medium containing 0.5 mg/ml of mitochondria. External Ca<sup>2 +</sup> concentration was measured fluorimetrically in the presence of 1 μM Calcium Green 5 N, a membrane impermeant Ca<sup>2 +</sup> probe increasing its fluorescence upon Ca<sup>2 +</sup> binding (excitation and emission wavelengths 503 and 525 nm, respectively). The CRC is the amount of Ca<sup>2 +</sup> taken up by mitochondria before the precipitous release that follows occurrence of the permeability transition. The CRC values observed at a given concentration of idebenone were normalized to the CRC obtained in the absence of the compound (CRC<sub>0</sub>).</p>
      </sec>
      <sec id="s0030">
        <label>2.4</label>
        <title>Cell culture and growth conditions</title>
        <p>HQB17 and RJ206 cells cybrids were generated by fusion of enucleated fibroblasts derived from one control (HQB17) and one LHON patient (RJ206, a kind gift of Anthony H. Schapira) into osteosarcoma 143B.Tk<sup>−</sup> cells deprived of their own mtDNA <xref rid="bb0215" ref-type="bibr">[43]</xref>. Complete mtDNA sequencing revealed that HQB17 belongs to haplogroup J1b (Antonio Torroni, personal communication). RJ206 cells harbor the G3460A/MT-ND1 LHON mutation causing the A52T amino acid substitution in MT-ND1 <xref rid="bb0190 bb0195" ref-type="bibr">[38,39]</xref>, which was reported to sharply reduce mitochondrial ATP synthesis driven by complex I substrates <xref rid="bb0220" ref-type="bibr">[44]</xref>. XTC.UC1 cells, derived from a human thyroid carcinoma, bear a C insertion at bp3571 in MT-ND1, generating a premature stop codon at amino acid 101 of ND1 subunit that prevents complex I assembly <xref rid="bb0200 bb0205" ref-type="bibr">[40,41]</xref>. Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin in a humidified incubator at 37 °C with 5% CO<sub>2</sub>.</p>
      </sec>
      <sec id="s0035">
        <label>2.5</label>
        <title>Mitochondrial membrane potential</title>
        <p>Mitochondrial membrane potential (Δψ<sub>m</sub>) in isolated organelles was measured using a Perkin-Elmer LS50B spectrofluorometer and evaluated based on the fluorescence quenching of Rhodamine 123. Mitochondria (0.5 mg/ml) were added to 2 ml of 130 mM KCl, 10 mM MOPS-Tris, 1 mM Pi-Tris, 10 μM EGTA, 0.15 μM Rhodamine 123, pH 7.4. The fluorescence of Rhodamine 123 was monitored at excitation and emission wavelengths of 503 and 523 nm, respectively, with the slit width set at 2.5 nm. After a short incubation to reach stabilization of the signal, further additions were as indicated in the legend to <xref rid="f0005" ref-type="fig">Fig. 1</xref>.</p>
        <p>For measurements of Δψ<sub>m</sub> in situ, cells were seeded onto 24 mm-diameter round glass coverslips and grown for 2 days in DMEM. Δψ<sub>m</sub> was measured based on the accumulation of TMRM in the presence of 1.6 μM CsH, which inhibits the multidrug resistance pump but not the PTP <xref rid="bb0210 bb0225" ref-type="bibr">[42,45]</xref>. Cells were incubated in bicarbonate- and phenol red-free Hank's balanced salt solution (Sigma) supplemented with 10 mM Hepes and 1.6 μM CsH and loaded with 20 nM TMRM for 30 min. At the end of each experiment, mitochondria were fully depolarized by the addition of 4 μM of the protonophore carbonylcyanide-<italic>p</italic>-trifluoromethoxyphenyl hydrazone (FCCP). Cellular fluorescence images were acquired with an Olympus IX71/IX51 inverted microscope equipped with a xenon light source (150 W) for epifluorescence illumination and with a digital camera. For detection of fluorescence 568 ± 25 nm bandpass excitation and 585 nm longpass emission filter settings were used. Images were collected with an exposure time of 100 ms (6% illumination intensity) using a 40X, 1.3 NA oil immersion objective (Olympus). Data were acquired and analyzed using Cell R software (Olympus). Clusters of several mitochondria (10–30) were identified as regions of interest, and fields not containing cells were taken as the background. Sequential digital images were acquired every minute, and the average fluorescence intensity of all relevant regions was recorded and stored for subsequent analysis.</p>
      </sec>
      <sec id="s0040">
        <label>2.6</label>
        <title>Mitochondrial NAD(P)H</title>
        <p>Cells were seeded as described above and incubated in bicarbonate- and phenol red-free Hank's balanced salt solution supplemented with 10 mM Hepes and 1.6 μM CsH for 30 min. Alamethicin (50 μM) was added at the end of each experiment to allow complete release of pyridine nucleotides from mitochondria. For detection of fluorescence 340 nm bandpass excitation and 465 nm longpass emission filter settings were used. Images were collected with an exposure time of 800 ms (100% illumination intensity) using a 40X, 1.3 NA oil immersion objective (Olympus).</p>
      </sec>
      <sec id="s0045">
        <label>2.7</label>
        <title>Oxygen consumption rate</title>
        <p>Oxygen consumption rate (OCR) in adherent cells was measured with an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica MA, USA). HQB17 and RJ206 cybrids, and XTC.UC1 cells were seeded in XF24 cell culture microplates (Seahorse Bioscience) at 2 × 10<sup>4</sup> cells/well in 200 μl of DMEM containing 4.5 g/l glucose (DMEM-high glucose) and incubated at 37 °C in 5% CO<sub>2</sub> for 24 h. Assays were initiated by replacing the growth medium in each well with 670 μl of unbuffered DMEM-high glucose prewarmed at 37 °C. The cells were incubated at 37 °C for 30 min to allow temperature and pH equilibration. After an OCR baseline measurement, 70 μl of oligomycin, FCCP, rotenone and antimycin A were sequentially added to each well to reach final concentrations of 1 μg/ml for oligomycin, 0.2 μM (cybrids) or 0.1 μM (XTC.UC1 cells) for FCCP, and 1 μM for rotenone and antimycin A. Data are expressed as pmol of O<sub>2</sub> per minute per 2 × 10<sup>4</sup> cells. At the end of each experiment the medium was removed and cells were incubated with 0.1 μM calcein-AM in 200 μl/well of Hank's balanced salt solution supplemented with 10 mM Hepes and 1.6 μM CsH for 30 min, at 37 °C. Calcein-labeled adherent cells were observed with the Olympus IX71/IX51 inverted microscope (excitation and emission 495 and 515 nm, respectively, exposure time 100 ms, 6% illumination intensity) using a 10X, 1.3 NA oil immersion objective (Olympus).</p>
      </sec>
      <sec id="s0050">
        <label>2.8</label>
        <title>Mitochondrial ATP synthesis</title>
        <p>The rate of mitochondrial ATP synthesis was measured in digitonin-permeabilized cells incubated in 150 mM KCl, 25 mM Tris–HCl, 2 mM EDTA, 0.1% BSA, 10 mM K-Pi, 0.1 mM MgCl<sub>2</sub>, pH 7.4, in the presence of the inhibitor of adenylate kinase (0.1 mM P<sup>1</sup>,P<sup>5</sup> -di(adenosine-5′) pentaphosphate) and of complex I substrates (5 mM malate and 5 mM pyruvate) by using the luciferin/luciferase assay <xref rid="bb0230" ref-type="bibr">[46]</xref>, as detailed by the manufacturer's instructions. Addition of luciferin/luciferase (which according to Sigma is lyophilized with MgSO<sub>4</sub>) increases the Mg<sup>2 +</sup> concentration to a level sufficient to allow activity of the enzyme, but still low enough to minimize the activity of oligomycin-insensitive ATPases. Thus, although the measured ATP synthesis rate was entirely of mitochondrial origin (as indicated by its full sensitivity to oligomycin) the actual figures may be underestimated because of the concomitant occurrence of ATP-hydrolyzing reactions. The reaction was started by addition of 0.1 mM ADP and chemiluminescence was determined as a function of time with a luminometer. The chemiluminescence signal was calibrated with an internal ATP standard after addition of 10 μM oligomycin. Data were normalized for citrate synthase activity <xref rid="bb0235" ref-type="bibr">[47]</xref>. Further additions are indicated in the figure legends.</p>
      </sec>
      <sec id="s0055">
        <label>2.9</label>
        <title>Statistics</title>
        <p>Unless otherwise stated in the figure legends, each experiment was repeated 3 times. Data are presented as average ± S.E. or, for clarity, as representative experiments (see figure legends for details).</p>
      </sec>
    </sec>
    <sec id="s0060">
      <label>3</label>
      <title>Results</title>
      <p>Following energization with succinate, mitochondria underwent a small and transient depolarization upon the addition of Ca<sup>2 +</sup>, which is the expected response to Ca<sup>2 +</sup> accumulation (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>A</italic>). Subsequent addition of 50 μM idebenone triggered fast and complete mitochondrial depolarization (<italic>trace a</italic>) which was delayed and partially prevented by CsA (<italic>trace b</italic>), consistent with the PTP-inducing effects of idebenone <xref rid="bb0180" ref-type="bibr">[36]</xref>. Idebenone caused the expected decrease of the CRC <xref rid="bb0180" ref-type="bibr">[36]</xref>, a sensitive measure of the propensity of the PTP to open; yet this effect was fully prevented by pretreatment of mitochondria with CsA (results not shown) or with DTT (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>B</italic>). The latter finding is novel and of some interest, because it suggests that idebenone may interact with a PTP regulatory site that is sensitive to oxidation-reduction events. This point was investigated further. Following accumulation of a permissive Ca<sup>2 +</sup> load isolated mitochondria treated with idebenone underwent the expected PTP-mediated swelling response (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>C</italic>, <italic>trace a</italic>), while pore opening was prevented by treatment with a low concentration of N-ethylmaleimide (<xref rid="f0005" ref-type="fig">Fig. 1</xref><italic>C</italic>, <italic>trace b</italic>), which we have shown to block PTP-regulating sulfhydryl groups that are also sensitive to reduction with DTT <xref rid="bb0240" ref-type="bibr">[48]</xref>.</p>
      <p>We next tested the effects of idebenone on Δψ<sub>m</sub> in intact cells based on accumulation of TMRM in HQB17 cybrids containing normal mtDNA. Addition of 50 μM idebenone was followed by a rapid drop of fluorescence of TMRM (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>A, trace a</italic>), which indicates fast mitochondrial depolarization. This fluorescence decrease was largely prevented by treatment with both CsA (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>A, trace b</italic>) and decylubiquinone (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>A, trace c</italic>), reagents that inhibit the PTP at different sites <xref rid="bb0245" ref-type="bibr">[49]</xref>. Since prolonged openings of the PTP are followed by membrane permeabilization to pyridine nucleotides <xref rid="bb0250" ref-type="bibr">[50]</xref>, we also monitored mitochondrial NAD(P)H levels, which were rapidly decreased by the addition of idebenone (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>B, trace a</italic>) in a process that was prevented by CsA (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>B, trace b)</italic> or decylubiquinone (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>B</italic>, <italic>trace c</italic>) but still inducible with the pore-forming peptide alamethicin (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>B</italic>). Addition of rotenone after idebenone or alamethicin was not followed by NAD(P)<sup>+</sup> reduction (<xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>B</italic>), indicating that PTP opening (or alamethicin addition) causes the release of mitochondrial pyridine nucleotides rather than just their oxidation, at variance from treatment with FCCP alone (results not shown). The PTP-inducing effects of idebenone could be due to increased production of ROS, which has been shown to occur upon treatement of submitochondrial particles with this compound <xref rid="bb0060 bb0255" ref-type="bibr">[12,51]</xref>.</p>
      <p>The bioenergetic consequences of treatment with idebenone were also assessed by measurements of oxygen consumption with the sensitive Seahorse technology. Respiration of HQB17 cells was substantially inhibited by oligomycin, indicating a good phosphorylation capacity; it was stimulated well above basal levels by uncoupler, indicating a large respiratory reserve; and it could be largely inhibited by rotenone with no further effects of antimycin A (<xref rid="f0015" ref-type="fig">Fig. 3</xref>, <italic>open symbols</italic>). Addition of 50 μM idebenone was followed by a decreased OCR, which could no longer be stimulated by FCCP (<xref rid="f0015" ref-type="fig">Fig. 3</xref>, <italic>gray symbols</italic>). The protective effects of CsA were negligible (<xref rid="f0015" ref-type="fig">Fig. 3</xref>, <italic>closed symbols</italic>), in spite of preservation of the pyridine nucleotide pool.</p>
      <p>We then tested whether the PTP-inducing effects of idebenone observed in isolated mitochondria could be prevented by reduction with DTT in cells as well. DTT alone was unable to sustain the membrane potential after addition of rotenone to oligomycin-treated HQB17 cells (<xref rid="f0020" ref-type="fig">Fig. 4</xref><italic>A</italic>). Strikingly, however, the addition of DTT plus idebenone (i) prevented the depolarizing effects otherwise induced by the latter (<xref rid="f0020" ref-type="fig">Fig. 4</xref><italic>B</italic>, compare with <xref rid="f0010" ref-type="fig">Fig. 2</xref><italic>A</italic>); and (ii) allowed maintenance of the mitochondrial membrane potential after inhibition of complex I by rotenone, depolarization requiring the addition of antimycin A (<xref rid="f0020" ref-type="fig">Fig. 4</xref><italic>B</italic>). These results are consistent with electron transfer to complex III. We assessed whether this effect could be also observed after treatment of cells with idebenol obtained by reduction of idebenone with sodium dithionite <xref rid="bb0260" ref-type="bibr">[52]</xref>. Treatment of HQB17 (<xref rid="f0025" ref-type="fig">Fig. 5</xref><italic>A</italic>), RJ206 (<xref rid="f0025" ref-type="fig">Fig. 5</xref><italic>B</italic>) or XTC.UC1 cells (<xref rid="f0025" ref-type="fig">Fig. 5</xref><italic>C</italic>) with rotenone plus oligomycin caused a rapid depolarization (<italic>open symbols, trace a</italic> in all <italic>panels</italic>) suggesting that oxidation of idebenol (i.e. generation of idebenone) causes sensitization of the PTP. Indeed, in the presence of CsA the Δψ<sub>m</sub> was preserved and depolarization was only observed after the addition of antimycin A (<italic>closed symbols, trace b</italic> in all <italic>panels</italic>), indicating electron feeding at complex III.</p>
      <p>The next questions we addressed were whether idebenol can improve respiratory performance in cells where activity of complex I is compromised, and whether inhibition of complex I occurs in cells with a normal respiratory function. To answer these questions we studied respiration of HQB17 (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>A,A′</italic>), RJ206 (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>B,B′</italic>) and XTC.UC1 cells (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>C,C′</italic>).</p>
      <p>In HQB17 cells the addition of idebenol decreased basal respiration, which showed virtually no response to oligomycin, FCCP and rotenone (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>A</italic>; compare with <italic>dashed trace</italic> for the same experiment carried out in the absence of idebenol, data taken from <xref rid="f0015" ref-type="fig">Fig. 3</xref>). This behavior presumably reflects PTP opening by idebenone which forms during idebenol oxidation (<xref rid="f0010" ref-type="fig">Fig. 2</xref>, see also below). Indeed, addition of DTT plus idebenone had a marginal effect on basal respiration, which maintained sensitivity to oligomycin (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>A′</italic>). OCR could not be stimulated further by FCCP, but it became insensitive to rotenone while it could be inhibited by antimycin A, consistent with direct electron transfer to complex III (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>A′</italic>). DTT alone inhibited maximal respiration, suggesting that the inhibitory effect on complex I may be caused by DTT rather than idebenol. In the absence of idebenol DTT was unable to sustain respiration after addition of rotenone (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>A′</italic>).</p>
      <p>RJ206 cells displayed a lower OCR than wild-type cells and a normal response to oligomycin, but could not be stimulated beyond the initial rate by FCCP, indicating no reserve respiratory capacity (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>B</italic>). Like in HQB17 cybrids, treatment with idebenol made respiration totally insensitive to oligomycin, FCCP and rotenone (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>B</italic>). Also in this case, DTT plus idebenone allowed coupled (i.e. oligomycin-sensitive) respiration to occur in spite of a marked toxicity of DTT alone (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>B′</italic>).</p>
      <p>XTC.UC1 cells slightly improved their performance after the addition of idebenol, and displayed a very remarkable increase of the oligomycin-sensitive (i.e., phosphorylating) OCR with DTT plus idebenone in spite of the inhibitory effect of DTT alone (<xref rid="f0030" ref-type="fig">Fig. 6</xref><italic>C′</italic>).</p>
      <p>We finally directly assessed the effects of idebenone and idebenol on ATP production with different substrates and inhibitors. It should be noted that in these experiments no Ca<sup>2 +</sup> was added thus preventing PTP opening which is strictly Ca<sup>2 +</sup>-dependent. Remarkably, idebenol improved ATP synthesis in all cell types, and it allowed oxidative phosphorylation to proceed after inhibition of complex I with rotenone and of succinate dehydrogenase with malonate (<xref rid="f0035" ref-type="fig">Fig. 7</xref>). The rate of ATP synthesis could not be stimulated further by glycerol-3-phosphate (results not shown).</p>
    </sec>
    <sec id="s0065">
      <label>4</label>
      <title>Discussion</title>
      <p>In this study we have characterized the effects of idebenone and idebenol on mitochondrial bioenergetics. We have shown (i) that idebenone induces PTP opening in isolated mitochondria <xref rid="bb0180" ref-type="bibr">[36]</xref> through a redox-sensitive site that can be protected by N-ethylmaleimide or by reduction with DTT, an observation that proved instrumental in dissecting the complex effects of idebenone and idebenol in intact cells; (ii) that idebenone induces PTP opening also in intact HQB17 cells; under these circumstances idebenone does not mediate electron transfer between NAD(P)H and respiratory complex III; and (iii) that in the presence of DTT added idebenone (which presumably is fully reduced to idebenol) does not have PTP-inducing effects in cells and it allows rotenone-insensitive electron transfer to complex III of the respiratory chain, in a process that profoundly ameliorates the bioenergetic performance of XTC.UC1 cells lacking complex I. Interestingly, idebenol has mixed effects, i.e. it can sensitize the PTP and/or cause respiratory inhibition presumably because of the idebenone generated by its oxidation, as also shown by sensitization of the PTP to opening (which can be revealed by depolarization following the addition of oligomycin and rotenone). These results are novel because the effects of idebenone on mitochondrial bionergetics (specifically, the possible occurrence of PTP opening) had never been assessed in intact cells; and they are relevant to LHON, a maternally inherited disease due to primary mitochondrial DNA mutations affecting complex I <xref rid="bb0265" ref-type="bibr">[53]</xref>.</p>
      <p>Reduced ATP synthesis and increased oxidative stress are believed to sensitize retinal ganglion cells to apoptosis, which leads to blindness <xref rid="bb0270 bb0275 bb0280 bb0285" ref-type="bibr">[54–57]</xref>. Recent evidence suggests that the PTP may be involved in the pathophysiology of this disease <xref rid="bb0205" ref-type="bibr">[41]</xref>, and the possible occurrence of a permeability transition following treatment with idebenone is therefore of major concern, particularly in view of the fact that the preparation used in clinical trial is the oxidized form of the drug. Our finding that DTT plus idebenone is free of PTP-inducing effects and allows rotenone-insensitive electron transfer to complex III is therefore of interest to the development of treatments useful to bypass the defects of complex I.</p>
      <p>Idebenone strongly activates glycerol phosphate oxidation in brown adipose tissue mitochondria, an effect that could be traced to release of the inhibition of glycerol phosphate dehydrogenase by endogenous free fatty acids <xref rid="bb0290" ref-type="bibr">[58]</xref>. We did not observe stimulation of ATP production by glycerol-3-phosphate in digitonin-permeabilized HQB17, RJ206 and XTC.UC1 cells treated with idebenone (results not shown), suggesting that idebenone is not reduced by glycerol phosphate dehydrogenase in these cells. The possibility that this occurs in other cell types must, however, be borne in mind.</p>
      <p>A pathway for electron transfer from NADH to mitochondria has recently been identified with the demonstration that idebenone is a good substrate of cytosolic dicoumarol-sensitive NQO1 <xref rid="bb0175" ref-type="bibr">[35]</xref>; and that rescue of ATP levels by idebenone in different cell types correlated with expression of NQO1, which may provide an effective electron transfer from cytosolic NAD(P)H to idebenone and then complex III, thus reducing lactic acidosis in patients with complex I deficiency <xref rid="bb0175" ref-type="bibr">[35]</xref>. Remarkably, administration of 400 mg/kg/day of idebenone to mice for 4 weeks significantly slowed down the depletion of ATP induced by rotenone in isolated hepatocytes that had not been further treated with the drug <xref rid="bb0175" ref-type="bibr">[35]</xref>. In our cell lines rotenone-insensitive respiration in the presence of idebenol was not inhibited by dicoumarol (results not shown), suggesting that idebenone is not reduced by NQO1. This is consistent with PTP sensitization and inhibition of respiration in the course of idebenol oxidation, which we explain with generation of idebenone (<xref rid="f0025 f0030" ref-type="fig">Figs. 5 and 6</xref>).</p>
      <p>Besides anecdotal reports on the effects of idebenone therapy in various conditions <xref rid="bb0065 bb0070 bb0075 bb0080 bb0085" ref-type="bibr">[13–17]</xref>, the largest experience has been on patients with LHON both through a prospective controlled trial <xref rid="bb0145" ref-type="bibr">[29]</xref> and a retrospective re-evaluation of large cohorts of treated patients <xref rid="bb0150" ref-type="bibr">[30]</xref>. These studies revealed some efficacy although a subclass of patients is poor responders <xref rid="bb0145 bb0150" ref-type="bibr">[29,30]</xref>. The pathogenic mechanism of the different LHON mutations, which has not been fully elucidated yet, may be relevant to the variable success of idebenone in compensating complex I dysfunction. Furthermore, it should be mentioned that genetic variation in NQO1 <xref rid="bb0295 bb0300" ref-type="bibr">[59,60]</xref>, as well as in mtDNA haplogroups potentially regulating respiratory chain coupling and antioxidant enzymes, are putative modifiers of the therapeutic response to idebenone in LHON.</p>
      <p>The in vivo studies provided encouraging clinical evidence that idebenone is safe and well tolerated. Since idebenone is transformed into its metabolites QS-10, QS-6 and QS-4 within minutes of administration, and parent idebenone is not detectable in plasma after about 1 h <xref rid="bb0110 bb0305" ref-type="bibr">[22,61]</xref>, we suspect that the beneficial effects are not due to idebenone itself but to one of its longer-lasting metabolites. An attractive candidate appeared to be the carboxy derivative QS-10, which is a good electron acceptor from NQO1; yet QS-10 failed to restore ATP levels and to decrease lactate production in MELAS cells <xref rid="bb0175" ref-type="bibr">[35]</xref>. It will be important to test the mitochondrial effects of idebenone metabolites in order to identify the active species, a strategy that should provide effective and safer compounds devoid of the potentially toxic PTP-inducing properties of idebenone <xref rid="bb0180 bb0310" ref-type="bibr">[36,62]</xref>.</p>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="bb0005">
        <label>1</label>
        <element-citation publication-type="journal" id="rf0005">
          <person-group person-group-type="author">
            <name>
              <surname>Geromel</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Darin</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Chrétien</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Bénit</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>DeLonlay</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rötig</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Munnich</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Coenzyme Q<sub>10</sub> and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits</article-title>
          <source>Mol. Genet. Metab.</source>
          <volume>77</volume>
          <year>2002</year>
          <fpage>21</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">12359126</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0010">
        <label>2</label>
        <element-citation publication-type="journal" id="rf0010">
          <person-group person-group-type="author">
            <name>
              <surname>Bentinger</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Tekle</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dallner</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Coenzyme Q—biosynthesis and functions</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>396</volume>
          <year>2010</year>
          <fpage>74</fpage>
          <lpage>79</lpage>
          <pub-id pub-id-type="pmid">20494114</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0015">
        <label>3</label>
        <element-citation publication-type="journal" id="rf0015">
          <person-group person-group-type="author">
            <name>
              <surname>Quinzii</surname>
              <given-names>C.M.</given-names>
            </name>
            <name>
              <surname>Hirano</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Coenzyme Q and mitochondrial disease</article-title>
          <source>Dev. Disabil. Res. Rev.</source>
          <volume>16</volume>
          <year>2010</year>
          <fpage>183</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="pmid">20818733</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0020">
        <label>4</label>
        <element-citation publication-type="journal" id="rf0020">
          <person-group person-group-type="author">
            <name>
              <surname>Rotig</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Appelkvist</surname>
              <given-names>E.L.</given-names>
            </name>
            <name>
              <surname>Geromel</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Chretien</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Kadhom</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Edery</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lebideau</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Dallner</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Munnich</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ernster</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency</article-title>
          <source>Lancet</source>
          <volume>356</volume>
          <year>2000</year>
          <fpage>391</fpage>
          <lpage>395</lpage>
          <pub-id pub-id-type="pmid">10972372</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0025">
        <label>5</label>
        <element-citation publication-type="journal" id="rf0025">
          <person-group person-group-type="author">
            <name>
              <surname>Ernster</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Dallner</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Biochemical, physiological and medical aspects of ubiquinone function</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1271</volume>
          <year>1995</year>
          <fpage>195</fpage>
          <lpage>204</lpage>
          <pub-id pub-id-type="pmid">7599208</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0030">
        <label>6</label>
        <element-citation publication-type="journal" id="rf0030">
          <person-group person-group-type="author">
            <name>
              <surname>DiMauro</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A critical approach to the therapy of mitochondrial respiratory chain and oxidative phosphorylation diseases</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1792</volume>
          <year>2009</year>
          <fpage>1159</fpage>
          <lpage>1167</lpage>
          <pub-id pub-id-type="pmid">19026744</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0035">
        <label>7</label>
        <element-citation publication-type="journal" id="rf0035">
          <person-group person-group-type="author">
            <name>
              <surname>Rotig</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sidi</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Munnich</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Molecular insights into Friedreich's ataxia and antioxidant-based therapies</article-title>
          <source>Trends Mol. Med.</source>
          <volume>8</volume>
          <year>2002</year>
          <fpage>221</fpage>
          <lpage>224</lpage>
          <pub-id pub-id-type="pmid">12067631</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0040">
        <label>8</label>
        <element-citation publication-type="journal" id="rf0040">
          <person-group person-group-type="author">
            <name>
              <surname>Sugiyama</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Matsumoto</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Okamoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Imada</surname>
              <given-names>I.</given-names>
            </name>
          </person-group>
          <article-title>Effects of idebenone (CV-2619) and its metabolites on respiratory activity and lipid peroxidation in brain mitochondria from rats and dogs</article-title>
          <source>J. Pharmacobiodyn.</source>
          <volume>8</volume>
          <year>1985</year>
          <fpage>1006</fpage>
          <lpage>1017</lpage>
          <pub-id pub-id-type="pmid">2871147</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0045">
        <label>9</label>
        <element-citation publication-type="journal" id="rf0045">
          <person-group person-group-type="author">
            <name>
              <surname>Degli Esposti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Ngo</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ghelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Benelli</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>McLennan</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Linnane</surname>
              <given-names>A.W.</given-names>
            </name>
          </person-group>
          <article-title>The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <volume>330</volume>
          <year>1996</year>
          <fpage>395</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">8660670</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0050">
        <label>10</label>
        <element-citation publication-type="journal" id="rf0050">
          <person-group person-group-type="author">
            <name>
              <surname>Brière</surname>
              <given-names>J.J.</given-names>
            </name>
            <name>
              <surname>Schlemmer</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Chretien</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Rustin</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Quinone analogues regulate mitochondrial substrate competitive oxidation</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <volume>316</volume>
          <year>2004</year>
          <fpage>1138</fpage>
          <lpage>1142</lpage>
          <pub-id pub-id-type="pmid">15044103</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0055">
        <label>11</label>
        <element-citation publication-type="journal" id="rf0055">
          <person-group person-group-type="author">
            <name>
              <surname>Fato</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bergamini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Bortolus</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Maniero</surname>
              <given-names>A.L.</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ohnishi</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Lenaz</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Differential effects of mitochondrial Complex I inhibitors on production of reactive oxygen species</article-title>
          <source>Biochim. Biophys. Acta</source>
          <volume>1787</volume>
          <year>2009</year>
          <fpage>384</fpage>
          <lpage>392</lpage>
          <pub-id pub-id-type="pmid">19059197</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0060">
        <label>12</label>
        <element-citation publication-type="journal" id="rf0060">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Sharpley</surname>
              <given-names>M.S.</given-names>
            </name>
            <name>
              <surname>Hirst</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Reduction of hydrophilic ubiquinones by the flavin in mitochondrial NADH:ubiquinone oxidoreductase (Complex I) and production of reactive oxygen species</article-title>
          <source>Biochemistry</source>
          <volume>48</volume>
          <year>2009</year>
          <fpage>2053</fpage>
          <lpage>2062</lpage>
          <pub-id pub-id-type="pmid">19220002</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0065">
        <label>13</label>
        <element-citation publication-type="journal" id="rf0065">
          <person-group person-group-type="author">
            <name>
              <surname>Cortelli</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Montagna</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Pierangeli</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lodi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Barboni</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Liguori</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Iotti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Zaniol</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Lugaresi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Barbiroli</surname>
              <given-names>B.</given-names>
            </name>
          </person-group>
          <article-title>Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>148</volume>
          <year>1997</year>
          <fpage>25</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">9125387</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0070">
        <label>14</label>
        <element-citation publication-type="journal" id="rf0070">
          <person-group person-group-type="author">
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Barboni</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Zacchini</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mancini</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Monari</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Cevoli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Liguori</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Sensi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lugaresi</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Montagna</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>160</volume>
          <year>1998</year>
          <fpage>183</fpage>
          <lpage>188</lpage>
          <pub-id pub-id-type="pmid">9849804</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0075">
        <label>15</label>
        <element-citation publication-type="journal" id="rf0075">
          <person-group person-group-type="author">
            <name>
              <surname>Mashima</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Kigasawa</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Wakakura</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Oguchi</surname>
              <given-names>Y.</given-names>
            </name>
          </person-group>
          <article-title>Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?</article-title>
          <source>J. Neuroophthalmol.</source>
          <volume>20</volume>
          <year>2000</year>
          <fpage>166</fpage>
          <lpage>170</lpage>
          <pub-id pub-id-type="pmid">11001192</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0080">
        <label>16</label>
        <element-citation publication-type="journal" id="rf0080">
          <person-group person-group-type="author">
            <name>
              <surname>Sadun</surname>
              <given-names>A.A.</given-names>
            </name>
            <name>
              <surname>Morgia</surname>
              <given-names>C.L.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>Leber's hereditary optic neuropathy</article-title>
          <source>Curr. Treat. Options. Neurol.</source>
          <volume>13</volume>
          <year>2011</year>
          <fpage>109</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="pmid">21063922</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0085">
        <label>17</label>
        <element-citation publication-type="journal" id="rf0085">
          <person-group person-group-type="author">
            <name>
              <surname>Barnils</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Mesa</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Munoz</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Ferrer-Artola</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Arruga</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Response to idebenone and multivitamin therapy in Leber's hereditary optic neuropathy</article-title>
          <source>Arch. Soc. Esp. Oftalmol.</source>
          <volume>82</volume>
          <year>2007</year>
          <fpage>377</fpage>
          <lpage>380</lpage>
          <pub-id pub-id-type="pmid">17573650</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0090">
        <label>18</label>
        <element-citation publication-type="journal" id="rf0090">
          <person-group person-group-type="author">
            <name>
              <surname>Ihara</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Namba</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Kuroda</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Sato</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Shirabe</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>90</volume>
          <year>1989</year>
          <fpage>263</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="pmid">2738608</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0095">
        <label>19</label>
        <element-citation publication-type="journal" id="rf0095">
          <person-group person-group-type="author">
            <name>
              <surname>Ikejiri</surname>
              <given-names>Y.</given-names>
            </name>
            <name>
              <surname>Mori</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ishii</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Nishimoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Yasuda</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS</article-title>
          <source>Neurology</source>
          <volume>47</volume>
          <year>1996</year>
          <fpage>583</fpage>
          <lpage>585</lpage>
          <pub-id pub-id-type="pmid">8757046</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0100">
        <label>20</label>
        <element-citation publication-type="journal" id="rf0100">
          <person-group person-group-type="author">
            <name>
              <surname>Napolitano</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Salvetti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Vista</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Lombardi</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Siciliano</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Giraldi</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Long-term treatment with idebenone and riboflavin in a patient with MELAS</article-title>
          <source>Neurol. Sci.</source>
          <volume>21</volume>
          <year>2000</year>
          <fpage>S981</fpage>
          <lpage>S982</lpage>
          <pub-id pub-id-type="pmid">11382201</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0105">
        <label>21</label>
        <element-citation publication-type="journal" id="rf0105">
          <person-group person-group-type="author">
            <name>
              <surname>Haginoya</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Miyabayashi</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Kikuchi</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kojima</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Yamamoto</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Omura</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Uematsu</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Hino-Fukuyo</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Tsuchiya</surname>
              <given-names>S.</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of idebenone for respiratory failure in a patient with Leigh syndrome: a long-term follow-up study</article-title>
          <source>J. Neurol. Sci.</source>
          <volume>278</volume>
          <year>2009</year>
          <fpage>112</fpage>
          <lpage>114</lpage>
          <pub-id pub-id-type="pmid">19101701</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0110">
        <label>22</label>
        <element-citation publication-type="journal" id="rf0110">
          <person-group person-group-type="author">
            <name>
              <surname>Bodmer</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Vankan</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Dreier</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Kutz</surname>
              <given-names>K.W.</given-names>
            </name>
            <name>
              <surname>Drewe</surname>
              <given-names>J.</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetics and metabolism of idebenone in healthy male subjects</article-title>
          <source>Eur. J. Clin. Pharmacol.</source>
          <volume>65</volume>
          <year>2009</year>
          <fpage>493</fpage>
          <lpage>501</lpage>
          <pub-id pub-id-type="pmid">19125241</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0115">
        <label>23</label>
        <element-citation publication-type="journal" id="rf0115">
          <person-group person-group-type="author">
            <name>
              <surname>Meier</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Buyse</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Idebenone: an emerging therapy for Friedreich ataxia</article-title>
          <source>J. Neurol.</source>
          <volume>256</volume>
          <issue>Suppl 1</issue>
          <year>2009</year>
          <fpage>25</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="pmid">19283347</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0315">
        <label>24</label>
        <element-citation publication-type="journal" id="rf0300">
          <person-group person-group-type="author">
            <name>
              <surname>Mestre</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Coelho</surname>
              <given-names>M.M.</given-names>
            </name>
            <name>
              <surname>Rosa</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Sampaio</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic interventions for symptomatic treatment in Huntington's disease</article-title>
          <source>Cochrane. Database. Syst. Rev.</source>
          <year>2009</year>
          <fpage>CD006456</fpage>
          <pub-id pub-id-type="pmid">19588393</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0125">
        <label>25</label>
        <element-citation publication-type="journal" id="rf0120">
          <person-group person-group-type="author">
            <name>
              <surname>Gillis</surname>
              <given-names>J.C.</given-names>
            </name>
            <name>
              <surname>Benefield</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>McTavish</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders</article-title>
          <source>Drugs Aging</source>
          <volume>5</volume>
          <year>1994</year>
          <fpage>133</fpage>
          <lpage>152</lpage>
          <pub-id pub-id-type="pmid">7981485</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0130">
        <label>26</label>
        <element-citation publication-type="journal" id="rf0125">
          <person-group person-group-type="author">
            <name>
              <surname>Weyer</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Babej-Dolle</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Hadler</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Hofmann</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Herrmann</surname>
              <given-names>W.M.</given-names>
            </name>
          </person-group>
          <article-title>A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease</article-title>
          <source>Neuropsychobiology</source>
          <volume>36</volume>
          <year>1997</year>
          <fpage>73</fpage>
          <lpage>82</lpage>
          <pub-id pub-id-type="pmid">9267856</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0135">
        <label>27</label>
        <element-citation publication-type="journal" id="rf0130">
          <person-group person-group-type="author">
            <name>
              <surname>Gutzmann</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Hadler</surname>
              <given-names>D.</given-names>
            </name>
          </person-group>
          <article-title>Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study</article-title>
          <source>J. Neural Transm. Suppl.</source>
          <volume>54</volume>
          <year>1998</year>
          <fpage>301</fpage>
          <lpage>310</lpage>
          <pub-id pub-id-type="pmid">9850939</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0140">
        <label>28</label>
        <element-citation publication-type="journal" id="rf0135">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Tanaka</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Han</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Senzaki</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Kameyama</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Nabeshima</surname>
              <given-names>T.</given-names>
            </name>
          </person-group>
          <article-title>Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1–42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo</article-title>
          <source>Eur. J. Neurosci.</source>
          <volume>11</volume>
          <year>1999</year>
          <fpage>83</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="pmid">9987013</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0145">
        <label>29</label>
        <mixed-citation publication-type="other">T. Klopstock, P. Yu-Wai-Man, K. Dimitriadis, J. Rouleau, S. Heck, M. Bailie, A. Atawan, S. Chattopadhyay, M. Schubert, A. Garip, M. Kernt, D. Petraki, C. Rummey, M. Leinonen, G. Metz, P.G. Griffiths, T. Meier, P.F. Chinnery, A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy, BRAIN 134 (2011) 2677–2686.</mixed-citation>
      </ref>
      <ref id="bb0150">
        <label>30</label>
        <mixed-citation publication-type="other">V. Carelli, C. La Morgia, L.M. Valentino, G. Rizzo, M. Carbonelli, A.M. De Negri, F. Sadun, A. Carta, S. Guerriero, F. Simonelli, A.A. Sadun, D. Aggarwal, R. Liguori, P. Avoni, A. Baruzzi, M. Zeviani, P. Montagna, P. Barboni, Idebenone treatment In Leber's hereditary optic neuropathy, BRAIN 134 (2011) e188.</mixed-citation>
      </ref>
      <ref id="bb0155">
        <label>31</label>
        <element-citation publication-type="journal" id="rf0140">
          <person-group person-group-type="author">
            <name>
              <surname>Duveau</surname>
              <given-names>D.Y.</given-names>
            </name>
            <name>
              <surname>Arce</surname>
              <given-names>P.M.</given-names>
            </name>
            <name>
              <surname>Schoenfeld</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Raghav</surname>
              <given-names>N.</given-names>
            </name>
            <name>
              <surname>Cortopassi</surname>
              <given-names>G.A.</given-names>
            </name>
            <name>
              <surname>Hecht</surname>
              <given-names>S.M.</given-names>
            </name>
          </person-group>
          <article-title>Synthesis and characterization of mitoQ and idebenone analogues as mediators of oxygen consumption in mitochondria</article-title>
          <source>Bioorg. Med. Chem.</source>
          <volume>18</volume>
          <year>2010</year>
          <fpage>6429</fpage>
          <lpage>6441</lpage>
          <pub-id pub-id-type="pmid">20691600</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0160">
        <label>32</label>
        <element-citation publication-type="journal" id="rf0145">
          <person-group person-group-type="author">
            <name>
              <surname>Jauslin</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Meier</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>R.A.</given-names>
            </name>
            <name>
              <surname>Murphy</surname>
              <given-names>M.P.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants</article-title>
          <source>FASEB J.</source>
          <volume>17</volume>
          <year>2003</year>
          <fpage>1972</fpage>
          <lpage>1974</lpage>
          <pub-id pub-id-type="pmid">12923074</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0165">
        <label>33</label>
        <element-citation publication-type="journal" id="rf0150">
          <person-group person-group-type="author">
            <name>
              <surname>Gil</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>C.R.</given-names>
            </name>
            <name>
              <surname>Rego</surname>
              <given-names>A.C.</given-names>
            </name>
          </person-group>
          <article-title>Cytosolic and mitochondrial ROS in staurosporine-induced retinal cell apoptosis</article-title>
          <source>Free Radic. Biol. Med.</source>
          <volume>35</volume>
          <year>2003</year>
          <fpage>1500</fpage>
          <lpage>1514</lpage>
          <pub-id pub-id-type="pmid">14642398</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0170">
        <label>34</label>
        <element-citation publication-type="journal" id="rf0155">
          <person-group person-group-type="author">
            <name>
              <surname>Lim</surname>
              <given-names>C.K.</given-names>
            </name>
            <name>
              <surname>Kalinowski</surname>
              <given-names>D.S.</given-names>
            </name>
            <name>
              <surname>Richardson</surname>
              <given-names>D.R.</given-names>
            </name>
          </person-group>
          <article-title>Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class</article-title>
          <source>Mol. Pharmacol.</source>
          <volume>74</volume>
          <year>2008</year>
          <fpage>225</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="pmid">18424550</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0175">
        <label>35</label>
        <element-citation publication-type="journal" id="rf0160">
          <person-group person-group-type="author">
            <name>
              <surname>Haefeli</surname>
              <given-names>R.H.</given-names>
            </name>
            <name>
              <surname>Erb</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Gemperli</surname>
              <given-names>A.C.</given-names>
            </name>
            <name>
              <surname>Robay</surname>
              <given-names>D.</given-names>
            </name>
            <name>
              <surname>Courdier Fruh</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Anklin</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Dallmann</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Gueven</surname>
              <given-names>N.</given-names>
            </name>
          </person-group>
          <article-title>NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels</article-title>
          <source>PLoS One</source>
          <volume>6</volume>
          <year>2011</year>
          <fpage>e17963</fpage>
          <pub-id pub-id-type="pmid">21483849</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0180">
        <label>36</label>
        <element-citation publication-type="journal" id="rf0165">
          <person-group person-group-type="author">
            <name>
              <surname>Walter</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Nogueira</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Leverve</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Fontaine</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Three classes of ubiquinone analogs regulate the mitochondrial permeability transition pore through a common site</article-title>
          <source>J. Biol. Chem.</source>
          <volume>275</volume>
          <year>2000</year>
          <fpage>29521</fpage>
          <lpage>29527</lpage>
          <pub-id pub-id-type="pmid">10889201</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0185">
        <label>37</label>
        <element-citation publication-type="journal" id="rf0170">
          <person-group person-group-type="author">
            <name>
              <surname>Rasola</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sciacovelli</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Pantic</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Signal transduction to the permeability transition pore</article-title>
          <source>FEBS Lett.</source>
          <volume>584</volume>
          <year>2010</year>
          <fpage>1989</fpage>
          <lpage>1996</lpage>
          <pub-id pub-id-type="pmid">20153328</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0190">
        <label>38</label>
        <element-citation publication-type="journal" id="rf0175">
          <person-group person-group-type="author">
            <name>
              <surname>Ghelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Zanna</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Porcelli</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Schapira</surname>
              <given-names>A.H.V.</given-names>
            </name>
            <name>
              <surname>Martinuzzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Rugolo</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Leber's hereditary optic neuropathy (LHON) pathogenic mutations induce mitochondrial-dependent apoptotic death in transmitochondrial cells incubated with galactose medium</article-title>
          <source>J. Biol. Chem.</source>
          <volume>278</volume>
          <year>2003</year>
          <fpage>4145</fpage>
          <lpage>4150</lpage>
          <pub-id pub-id-type="pmid">12446713</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0195">
        <label>39</label>
        <element-citation publication-type="journal" id="rf0180">
          <person-group person-group-type="author">
            <name>
              <surname>Ghelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Porcelli</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Zanna</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Vidoni</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mattioli</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Barbieri</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Iommarini</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Pala</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Achilli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Torroni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Rugolo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>The background of mitochondrial DNA haplogroup J increases the sensitivity of Leber's hereditary optic neuropathy cells to 2,5-hexanedione toxicity</article-title>
          <source>PLoS One</source>
          <volume>4</volume>
          <year>2009</year>
          <fpage>e7922</fpage>
          <pub-id pub-id-type="pmid">19936068</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0200">
        <label>40</label>
        <element-citation publication-type="journal" id="rf0185">
          <person-group person-group-type="author">
            <name>
              <surname>Bonora</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Porcelli</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Gasparre</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Biondi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ghelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Baracca</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Tallini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Martinuzzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lenaz</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Rugolo</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Romeo</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III</article-title>
          <source>Cancer Res.</source>
          <volume>66</volume>
          <year>2006</year>
          <fpage>6087</fpage>
          <lpage>6096</lpage>
          <pub-id pub-id-type="pmid">16778181</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0205">
        <label>41</label>
        <element-citation publication-type="journal" id="rf0190">
          <person-group person-group-type="author">
            <name>
              <surname>Porcelli</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Angelin</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Ghelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Mariani</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Martinuzzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Petronilli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Rugolo</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Respiratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels</article-title>
          <source>J. Biol. Chem.</source>
          <volume>284</volume>
          <year>2009</year>
          <fpage>2045</fpage>
          <lpage>2052</lpage>
          <pub-id pub-id-type="pmid">19047048</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0210">
        <label>42</label>
        <element-citation publication-type="journal" id="rf0195">
          <person-group person-group-type="author">
            <name>
              <surname>Nicolli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Basso</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Petronilli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Wenger</surname>
              <given-names>R.M.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Interactions of cyclophilin with the mitochondrial inner membrane and regulation of the permeability transition pore, a cyclosporin A-sensitive channel</article-title>
          <source>J. Biol. Chem.</source>
          <volume>271</volume>
          <year>1996</year>
          <fpage>2185</fpage>
          <lpage>2192</lpage>
          <pub-id pub-id-type="pmid">8567677</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0215">
        <label>43</label>
        <element-citation publication-type="journal" id="rf0200">
          <person-group person-group-type="author">
            <name>
              <surname>King</surname>
              <given-names>M.P.</given-names>
            </name>
            <name>
              <surname>Attardi</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Isolation of human cell lines lacking mitochondrial DNA</article-title>
          <source>Methods Enzymol.</source>
          <volume>264</volume>
          <year>1996</year>
          <fpage>304</fpage>
          <lpage>313</lpage>
          <pub-id pub-id-type="pmid">8965704</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0220">
        <label>44</label>
        <element-citation publication-type="journal" id="rf0205">
          <person-group person-group-type="author">
            <name>
              <surname>Baracca</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Sgarbi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Solaini</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lenaz</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Rhodamine 123 as a probe of mitochondrial membrane potential: evaluation of proton flux through F0 during ATP synthesis</article-title>
          <source>Biochim. Biophys. Acta - Bioenergetics</source>
          <volume>1606</volume>
          <year>2003</year>
          <fpage>137</fpage>
          <lpage>146</lpage>
        </element-citation>
      </ref>
      <ref id="bb0225">
        <label>45</label>
        <element-citation publication-type="journal" id="rf0210">
          <person-group person-group-type="author">
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Scorrano</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Petronilli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Di Lisa</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondria and cell death. Mechanistic aspects and methodological issues</article-title>
          <source>Eur. J. Biochem.</source>
          <volume>264</volume>
          <year>1999</year>
          <fpage>687</fpage>
          <lpage>701</lpage>
          <pub-id pub-id-type="pmid">10491114</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0230">
        <label>46</label>
        <element-citation publication-type="journal" id="rf0215">
          <person-group person-group-type="author">
            <name>
              <surname>Manfredi</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Gajewski</surname>
              <given-names>C.D.</given-names>
            </name>
            <name>
              <surname>Mattiazzi</surname>
              <given-names>M.</given-names>
            </name>
          </person-group>
          <article-title>Measurements of ATP in mammalian cells</article-title>
          <source>Methods</source>
          <volume>26</volume>
          <year>2002</year>
          <fpage>317</fpage>
          <lpage>326</lpage>
          <pub-id pub-id-type="pmid">12054922</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0235">
        <label>47</label>
        <element-citation publication-type="journal" id="rf0220">
          <person-group person-group-type="author">
            <name>
              <surname>Srere</surname>
              <given-names>P.A.</given-names>
            </name>
            <name>
              <surname>Brooks</surname>
              <given-names>G.C.</given-names>
            </name>
          </person-group>
          <article-title>The circular dichroism of glucagon solutions</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <volume>129</volume>
          <year>1969</year>
          <fpage>708</fpage>
          <lpage>710</lpage>
          <pub-id pub-id-type="pmid">5772973</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0240">
        <label>48</label>
        <element-citation publication-type="journal" id="rf0225">
          <person-group person-group-type="author">
            <name>
              <surname>Petronilli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Costantini</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Scorrano</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Colonna</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Passamonti</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents</article-title>
          <source>J. Biol. Chem.</source>
          <volume>269</volume>
          <year>1994</year>
          <fpage>16638</fpage>
          <lpage>16642</lpage>
          <pub-id pub-id-type="pmid">7515881</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0245">
        <label>49</label>
        <element-citation publication-type="journal" id="rf0230">
          <person-group person-group-type="author">
            <name>
              <surname>Fontaine</surname>
              <given-names>E.</given-names>
            </name>
            <name>
              <surname>Ichas</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>A ubiquinone-binding site regulates the mitochondrial permeability transition pore</article-title>
          <source>J. Biol. Chem.</source>
          <volume>273</volume>
          <year>1998</year>
          <fpage>25734</fpage>
          <lpage>25740</lpage>
          <pub-id pub-id-type="pmid">9748242</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0250">
        <label>50</label>
        <element-citation publication-type="journal" id="rf0235">
          <person-group person-group-type="author">
            <name>
              <surname>Di Lisa</surname>
              <given-names>F.</given-names>
            </name>
            <name>
              <surname>Menabò</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Canton</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Barile</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD<sup>+</sup> and is a causative event in the death of myocytes in postischemic reperfusion of the heart</article-title>
          <source>J. Biol. Chem.</source>
          <volume>276</volume>
          <year>2001</year>
          <fpage>2571</fpage>
          <lpage>2575</lpage>
          <pub-id pub-id-type="pmid">11073947</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0255">
        <label>51</label>
        <element-citation publication-type="journal" id="rf0240">
          <person-group person-group-type="author">
            <name>
              <surname>Fato</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Bergamini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Leoni</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Lenaz</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial production of reactive oxygen species: role of complex I and quinone analogues</article-title>
          <source>Biofactors</source>
          <volume>32</volume>
          <year>2008</year>
          <fpage>31</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="pmid">19096098</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0260">
        <label>52</label>
        <element-citation publication-type="journal" id="rf0245">
          <person-group person-group-type="author">
            <name>
              <surname>Rieske</surname>
              <given-names>J.S.</given-names>
            </name>
          </person-group>
          <source>Methods Enzymol.</source>
          <volume>X</volume>
          <year>1967</year>
          <fpage>239</fpage>
          <lpage>245</lpage>
        </element-citation>
      </ref>
      <ref id="bb0265">
        <label>53</label>
        <element-citation publication-type="journal" id="rf0250">
          <person-group person-group-type="author">
            <name>
              <surname>Wallace</surname>
              <given-names>D.C.</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Lott</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>J.A.</given-names>
            </name>
            <name>
              <surname>Schurr</surname>
              <given-names>T.G.</given-names>
            </name>
            <name>
              <surname>Lezza</surname>
              <given-names>A.M.</given-names>
            </name>
            <name>
              <surname>Elsas</surname>
              <given-names>L.J.</given-names>
            </name>
            <name>
              <surname>Nikoskelainen</surname>
              <given-names>E.K.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy</article-title>
          <source>Science</source>
          <volume>242</volume>
          <year>1988</year>
          <fpage>1427</fpage>
          <lpage>1430</lpage>
          <pub-id pub-id-type="pmid">3201231</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0270">
        <label>54</label>
        <element-citation publication-type="journal" id="rf0255">
          <person-group person-group-type="author">
            <name>
              <surname>Brown</surname>
              <given-names>M.D.</given-names>
            </name>
            <name>
              <surname>Voljavec</surname>
              <given-names>A.S.</given-names>
            </name>
            <name>
              <surname>Lott</surname>
              <given-names>M.T.</given-names>
            </name>
            <name>
              <surname>MacDonald</surname>
              <given-names>I.</given-names>
            </name>
            <name>
              <surname>Wallace</surname>
              <given-names>D.C.</given-names>
            </name>
          </person-group>
          <article-title>Leber's hereditary optic neuropathy: a model for mitochondrial neurodegenerative diseases</article-title>
          <source>FASEB J.</source>
          <volume>6</volume>
          <year>1992</year>
          <fpage>2791</fpage>
          <lpage>2799</lpage>
          <pub-id pub-id-type="pmid">1634041</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0275">
        <label>55</label>
        <element-citation publication-type="journal" id="rf0260">
          <person-group person-group-type="author">
            <name>
              <surname>Beretta</surname>
              <given-names>S.</given-names>
            </name>
            <name>
              <surname>Mattavelli</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Sala</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Tremolizzo</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Schapira</surname>
              <given-names>A.H.</given-names>
            </name>
            <name>
              <surname>Martinuzzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Ferrarese</surname>
              <given-names>C.</given-names>
            </name>
          </person-group>
          <article-title>Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines</article-title>
          <source>Brain</source>
          <volume>127</volume>
          <year>2004</year>
          <fpage>2183</fpage>
          <lpage>2192</lpage>
          <pub-id pub-id-type="pmid">15342361</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0280">
        <label>56</label>
        <element-citation publication-type="journal" id="rf0265">
          <person-group person-group-type="author">
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
            <name>
              <surname>Ross-Cisneros</surname>
              <given-names>F.N.</given-names>
            </name>
            <name>
              <surname>Sadun</surname>
              <given-names>A.A.</given-names>
            </name>
          </person-group>
          <article-title>Mitochondrial dysfunction as a cause of optic neuropathies</article-title>
          <source>Prog. Retin. Eye Res.</source>
          <volume>23</volume>
          <year>2004</year>
          <fpage>53</fpage>
          <lpage>89</lpage>
          <pub-id pub-id-type="pmid">14766317</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0285">
        <label>57</label>
        <element-citation publication-type="journal" id="rf0270">
          <person-group person-group-type="author">
            <name>
              <surname>Valentino</surname>
              <given-names>M.L.</given-names>
            </name>
            <name>
              <surname>Barboni</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Ghelli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Bucchi</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Rengo</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Achilli</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Torroni</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lugaresi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Lodi</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Barbiroli</surname>
              <given-names>B.</given-names>
            </name>
            <name>
              <surname>Dotti</surname>
              <given-names>M.</given-names>
            </name>
            <name>
              <surname>Federico</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Baruzzi</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Carelli</surname>
              <given-names>V.</given-names>
            </name>
          </person-group>
          <article-title>The ND1 gene of complex I is a mutational hot spot for Leber's hereditary optic neuropathy</article-title>
          <source>Ann. Neurol.</source>
          <volume>56</volume>
          <year>2004</year>
          <fpage>631</fpage>
          <lpage>641</lpage>
          <pub-id pub-id-type="pmid">15505787</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0290">
        <label>58</label>
        <element-citation publication-type="journal" id="rf0275">
          <person-group person-group-type="author">
            <name>
              <surname>Rauchová</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Drahota</surname>
              <given-names>Z.</given-names>
            </name>
            <name>
              <surname>Bergamini</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Fato</surname>
              <given-names>R.</given-names>
            </name>
            <name>
              <surname>Lenaz</surname>
              <given-names>G.</given-names>
            </name>
          </person-group>
          <article-title>Modification of respiratory-chain enzyme activities in brown adipose tissue mitochondria by idebenone (hydroxydecyl-ubiquinone)</article-title>
          <source>J. Bioenerg. Biomembr.</source>
          <volume>40</volume>
          <year>2008</year>
          <fpage>85</fpage>
          <lpage>93</lpage>
          <pub-id pub-id-type="pmid">18368470</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0295">
        <label>59</label>
        <element-citation publication-type="journal" id="rf0280">
          <person-group person-group-type="author">
            <name>
              <surname>Dinkova-Kostova</surname>
              <given-names>A.T.</given-names>
            </name>
            <name>
              <surname>Talalay</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector</article-title>
          <source>Arch. Biochem. Biophys.</source>
          <volume>501</volume>
          <year>2010</year>
          <fpage>116</fpage>
          <lpage>123</lpage>
          <pub-id pub-id-type="pmid">20361926</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0300">
        <label>60</label>
        <element-citation publication-type="journal" id="rf0285">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>A.</given-names>
            </name>
            <name>
              <surname>Schmelzer</surname>
              <given-names>C.</given-names>
            </name>
            <name>
              <surname>Rimbach</surname>
              <given-names>G.</given-names>
            </name>
            <name>
              <surname>Niklowitz</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Menke</surname>
              <given-names>T.</given-names>
            </name>
            <name>
              <surname>Doring</surname>
              <given-names>F.</given-names>
            </name>
          </person-group>
          <article-title>Association between genetic variants in the Coenzyme Q10 metabolism and Coenzyme Q10 status in humans</article-title>
          <source>BMC. Res. Notes</source>
          <volume>4</volume>
          <year>2011</year>
          <fpage>245</fpage>
          <pub-id pub-id-type="pmid">21774831</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0305">
        <label>61</label>
        <element-citation publication-type="journal" id="rf0290">
          <person-group person-group-type="author">
            <name>
              <surname>Kutz</surname>
              <given-names>K.</given-names>
            </name>
            <name>
              <surname>Drewe</surname>
              <given-names>J.</given-names>
            </name>
            <name>
              <surname>Vankan</surname>
              <given-names>P.</given-names>
            </name>
          </person-group>
          <article-title>Pharmacokinetic properties and metabolism of idebenone</article-title>
          <source>J. Neurol.</source>
          <volume>256</volume>
          <issue>Suppl 1</issue>
          <year>2009</year>
          <fpage>31</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="pmid">19283348</pub-id>
        </element-citation>
      </ref>
      <ref id="bb0310">
        <label>62</label>
        <element-citation publication-type="journal" id="rf0295">
          <person-group person-group-type="author">
            <name>
              <surname>Walter</surname>
              <given-names>L.</given-names>
            </name>
            <name>
              <surname>Miyoshi</surname>
              <given-names>H.</given-names>
            </name>
            <name>
              <surname>Leverve</surname>
              <given-names>X.</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>P.</given-names>
            </name>
            <name>
              <surname>Fontaine</surname>
              <given-names>E.</given-names>
            </name>
          </person-group>
          <article-title>Regulation of the mitochondrial permeability transition pore by ubiquinone analogs. A progress report</article-title>
          <source>Free Radic. Res.</source>
          <volume>36</volume>
          <year>2002</year>
          <fpage>405</fpage>
          <lpage>412</lpage>
          <pub-id pub-id-type="pmid">12069104</pub-id>
        </element-citation>
      </ref>
    </ref-list>
    <ack>
      <title>Acknowledgments</title>
      <p>Supported by grants from <funding-source id="gts0005">Telethon — Italy</funding-source>
<italic>Therapeutic strategies to combat mitochondrial disorders</italic>, <funding-source id="gts0010">Fondazione Cariparo</funding-source>, <funding-source id="gts0015">Università di Padova Progetti di Eccellenza</funding-source>
<italic>Models of Mitochondrial Diseases</italic> and <funding-source id="gts0020">Progetti di Ricerca di Interesse Nazionale (PRIN)</funding-source>
<italic>Mitochondria as therapeutic targets in chronic degenerative diseases.</italic></p>
    </ack>
  </back>
  <floats-group>
    <fig id="f0005">
      <label>Fig. 1</label>
      <caption>
        <p>Effects of idebenone on mitochondrial membrane potential, Ca<sup>2 +</sup> retention capacity and volume. <italic>A</italic>, the incubation medium contained 130 mM KCl, 10 mM MOPS-Tris, 1 mM Pi-Tris, 10 μM EGTA, 0.15 μM Rhodamine 123, pH 7.4 and 0.8 μM CsA (<italic>trace b</italic> only); where indicated, 5 mM succinate (Succ), 35 μM Ca<sup>2 +</sup>, 50 μM idebenone (IdB) and 0.5 μM FCCP were added. <italic>B</italic>, the mitochondrial CRC was determined following the addition of 10 μM Ca<sup>2 +</sup> pulses, and values were normalized to the CRC obtained in the absence of idebenone (CRC<sub>0</sub>). Mitochondria were treated with the indicated concentrations of idebenone in the absence (<italic>closed symbols</italic>) or presence (<italic>open symbols</italic>) of 1 mM DTT. <italic>C</italic>, the incubation medium contained 0.25 M sucrose, 1 mM Pi-Tris, 10 mM MOPS-Tris, 20 μM EGTA-Tris, 5 mM glutamate-Tris, 2.5 mM malate-Tris. Where indicated 50 μM Ca<sup>2 +</sup>, 20 μM N-ethylmaleimide (NEM) and 50 μM idebenone (IdB) were added.</p>
      </caption>
      <graphic xlink:href="gr1"/>
    </fig>
    <fig id="f0010">
      <label>Fig. 2</label>
      <caption>
        <p>Effects of idebenone, CsA and decylubiquinone on mitochondrial TMRM accumulation and NAD(P)H levels. <italic>A</italic>, TMRM fluorescence and <italic>B</italic>, NAD(P)H fluorescence of HQB17 cells in the absence (<italic>open symbols, traces a</italic>) or presence of 1.6 μM CsA (<italic>closed squares, traces b</italic>) or 50 μM decylubiquinone (<italic>closed triangles, traces c</italic>). Where indicated 50 μM idebenone (IdB), 4 μM FCCP, 80 μM alamethicin (Ala) and 4 μM rotenone (R) were added. Data in both <italic>panels</italic> report one representative experiment of five (for idebenone and idebenone plus CsA) or three (idebenone plus decylubiquinone). The maximal S.E., which is omitted for clarity, was ± 10%.</p>
      </caption>
      <graphic xlink:href="gr2"/>
    </fig>
    <fig id="f0015">
      <label>Fig. 3</label>
      <caption>
        <p>Effects of idebenone on respiration of HQB17 cells. HQB17 cells were incubated in Seahorse 24-well plates (20,000 cells/well) and respiration measured in the absence (<italic>open circles</italic>) or presence of 50 μM idebenone alone (<italic>gray circles</italic>) or with 1.6 μM CsA (<italic>closed symbols</italic>). Where indicated 1 μg/mL oligomycin (O), 0.2 μM FCCP (F), 1 μM rotenone (R), and 1 μM antimycin A (AA) were added. Data report one representative experiment of three, and the maximal S.E. was ± 11.3 pmol oxygen/min. OCR, oxygen consumption rate.</p>
      </caption>
      <graphic xlink:href="gr3"/>
    </fig>
    <fig id="f0020">
      <label>Fig. 4</label>
      <caption>
        <p>Effects of DTT and idebenone on mitochondrial TMRM fluorescence in HQB17 cells. HQB17 cells were loaded with 10 nM TMRM. <italic>A</italic>, additions were 2 mM DTT, 5 μM oligomycin (O), 4 μM rotenone (R), 1 μM antimycin A (AA) and 4 μM FCCP (F); <italic>B</italic>, additions were 2 mM DTT plus 50 μM idebenone (DTT + IdB), 5 μM oligomycin (O), 4 μM rotenone (R), 1 μM antimycin A (AA) and 4 μM FCCP. Data are from three or six independent experiments for <italic>panels A</italic> and <italic>B</italic>, respectively.</p>
      </caption>
      <graphic xlink:href="gr4"/>
    </fig>
    <fig id="f0025">
      <label>Fig. 5</label>
      <caption>
        <p>Effects of idebenol on mitochondrial TMRM fluorescence in HQB17, RJ206 and XTC.UC1 cells. HQB17 (<italic>A</italic>), RJ206 (<italic>B</italic>) and XTC.UC1 cells (<italic>C</italic>) were loaded with 10 nM TMRM in the absence (<italic>open symbols</italic>) or presence (<italic>closed symbols</italic>) of 1.6 μM CsA, and changes in fluorescence were monitored by fluorescence microscopy. Where indicated 50 μM idebenol (IdBH<sub>2</sub>), 5 μM oligomycin plus 4 μM rotenone (O + R), 1 μM antimycin A (AA) and 4 μM FCCP were added. Data are from three, eleven and ten independent experiments for <italic>panels A</italic>, <italic>B</italic>, and <italic>C</italic>, respectively.</p>
      </caption>
      <graphic xlink:href="gr5"/>
    </fig>
    <fig id="f0030">
      <label>Fig. 6</label>
      <caption>
        <p>Idebenol and DTT-reduced idebenone promote basal respiration in XTC.UC1, but not in HQB17 and RJ206 cells. Cellular OCR of HQB17 (<italic>A, A′</italic>), RJ206 (<italic>B,B′</italic>) and XTC.UC1 cells (<italic>C,C′</italic>) was measured in 24-well Seahorse plates (20,000 cells/well). Cells were incubated in the absence of added quinone (<italic>open squares</italic>; the <italic>dashed trace</italic> in panel A is taken from <xref rid="f0015" ref-type="fig">Fig. 3</xref>). <italic>A–C</italic>, cells were supplemented with 50 μM idebenol (<italic>closed squares</italic>); <italic>A′-C′</italic>, cells were supplemented with 1 mM DTT (<italic>open circles</italic>) or 1 mM DTT plus 50 μM idebenone (<italic>closed circles</italic>). Note the different scale in <italic>panels A</italic> and <italic>A′</italic>. Data are representative of at least seven independent experiments, and the maximal variation (in pmol oxygen/min) was 12.5 (<italic>panel A</italic>), 3.1 (<italic>panel B</italic>), 7.5 (<italic>panel C</italic>), 9.9 (<italic>panel A′</italic>), 4.5 (<italic>panel B′</italic>), 4.3 (<italic>panel C′</italic>).</p>
      </caption>
      <graphic xlink:href="gr6"/>
    </fig>
    <fig id="f0035">
      <label>Fig. 7</label>
      <caption>
        <p>ATP synthesis in permeabilized HQB17, RJ206 and XTC.UC1 cells. HQB17 (<italic>A</italic>), RJ206 (<italic>B</italic>) and XTC.UC1 (<italic>C</italic>) cells were permeabilized with digitonin and rate of ATP synthesis was evaluated in the presence of 5 mM pyruvate and 5 mM malate (P/M), 50 μM idebenol (IdBH<sub>2</sub>), 50 μM idebenone (IdB), 5 μM rotenone and 5 mM malonate (Rot/Malon) as indicated. Asterisks denote values significantly different from P/M alone (P &lt; 0.05).</p>
      </caption>
      <graphic xlink:href="gr7"/>
    </fig>
  </floats-group>
</article>